Latin America Haemostatic Agents Market

Latin America Haemostatic Agents Market Size (2023 to 2028)

The size of the Haemostatic Agents Market in Latin America is predicted to grow at a steady rate from 2023 to 2028.

The rising number of trauma and surgical cases and technology advances are some of the factors propelling the Latin American hemostatic agents market. One of the primary factors of the Haemostatic product market's growth is an increase in the number of surgical procedures. Surgical care is necessary to handle a variety of health disorders, including cardiovascular illnesses, traumas, cancer, obstructed labor, birth deformities, and other conditions, as recognized by WHO and several other international organizations.

The increased hemorrhage frequency during surgery and the growing emphasis on blood control are further projected to drive the Latin American haemostatic agents market. Furthermore, technological advancements in surgical procedures, such as robot-assisted surgery, and an aging population are expected to drive demand in the haemostatic agents market in the Latin American region.

There has been an increase in the demand for hemostats as the prevalence of chronic diseases, cesarean deliveries, fatal injuries, and significant organ procedures has increased. These medications help patients with hemostatic disorders and nonanatomic and sensitive structures avoid blood loss during surgical procedures.

Aside from that, their use helps reduce treatment costs, which has led to their widespread adoption among healthcare professionals. Furthermore, due to technological breakthroughs, significant manufacturers have created absorbable adjunctive hemostats that assist professionals in controlling disruptive bleeding more effectively than traditional methods.

However, the market for haemostatic diagnostic analyzers and reagents is expected to be hampered by the high frequency of blood clotting disorders in countries such as Brazil and Argentina and a lack of awareness regarding haemostatic diagnostics in Latin America. In remote places, high per capita income has boosted the use of diagnostic and therapeutic agents, putting a significant strain on patient treatment. Several government standards and severe rules have been implemented to improve the healthcare infrastructure.

This research report on the Latin America haemostatic agents market has been segmented and sub-segmented into the following categories:

By Type: 

• Thrombin Based Haemostats
• Gelatin Based Haemostats
• Collagen Based Haemostats
• Oxidized Regenerated Cellulose Based Haemostats
• Combination Haemostats
• Fibrin Sealants
• Others

By Treatment: 

• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery 
• Others      

By End User: 

• Hospitals
• Surgery Centres
• Nursing Homes
• Others      

By Country: 

• Brazil
• Argentina
• Chile
• Mexico
• Rest of Latin America

Regionally, the Latin American region offers immense scope for development in the forecast years, as is evident from the region's high growth rate. Despite having only a minor market share, the CAGR of the region is the second-highest globally, only behind Asia-Pacific. Therefore, this market shows promise during the forecast period.

KEY MARKET PLAYERS:

Companies playing a significant role in the Latin America hemostatic agents market profiled in this report are Ethicon, Pfizer, Baxter International, R. Bard, The Medicines Company, Anika Therapeutics, Advanced Medical Solutions, Integra LifeSciences, B Braun Melsungen, Gelita Medical, Equimedical, Vascular Solutions, Marine Polymer Technologies, and Z-Medica.